Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Debate over THC potency caps pits patient access against public‑health concerns
Summary
A legislative working group heard competing testimony on whether Utah should cap THC potency for medical cannabis products: public‑health advocates urged limits to protect young people and reduce harms; patient representatives and pharmacists warned caps could drive patients to the illicit market and reduce therapeutic options.
Utah’s medical cannabis working group reopened a contentious question: should the state set limits on THC potency for medical cannabis products? The committee heard sharply divergent views from public‑health advocates, patients, pharmacists and industry representatives.
Senate staff presented a preliminary review of other states’ approaches: Connecticut and Vermont cap flower at 30% THC and concentrates at 60%, Massachusetts caps concentrates at 70%, and Mississippi (medical program only) caps flower at 30% and concentrates at 60%. The chair noted Utah law already limits 28‑day purchase quantities but is silent on potency caps.
Walter Plumb of Drug Safe Utah urged strict limits, citing research he said…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
